ArticleResearch square2025
Pembrolizumab and Olaparib (POLAR) Maintenance Therapy in Metastatic Pancreatic Cancer With or Without Homologous Repair Deficiency: A Biomarker Selected Phase II Trial.
Abstract readPreprint
In one paragraph
Article in Research square, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
66 authors.
Wungki ParkMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-8006-3102
Catherine O'ConnorHarvard Medical School, Boston, MA, USA, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.
Joanne ChouMemorial Sloan Kettering Cancer Center.
Marc HilmiMSKCC.ORCID 0000-0003-4762-6740
Zeynep TarcanHuman Oncology and Pathogenesis Program, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.
Carly SchwartzDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research.
Mary LarsenDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research.
Walid ChatilaMemorial Sloan Kettering Cancer Center.ORCID 0000-0001-5474-218X
Karthigayini SivaprakasamDepartment of Pathology and Laboratory Medicine, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center.
Shigeaki UmedaMemorial Sloan Kettering Cancer Center.ORCID 0000-0001-5693-1515
Maria PerryMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-8789-251X
Anna VargheseMemorial Sloan Kettering Cancer Center.ORCID 0000-0001-5426-0885
Kenneth YuMemorial Sloan Kettering Cancer Center.
Fiyinfolu BalogunMemorial Sloan Kettering Cancer Center.ORCID 0000-0003-4703-1560
Alice ZervoudakisDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Seth KatzDepartment of Radiology, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.
Tae-Hyung KimDepartment of Radiology, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.
Ken ZhaoDepartment of Radiology, Memorial Sloan Kettering Cancer Center.
Allison RichardsMemorial Sloan Kettering Cancer Center.
Nicolas LecomteMemorial Sloan Kettering Cancer Center.
Daniel MuldoonMemorial Sloan Kettering Cancer Center.ORCID 0000-0001-7936-4365
Elias KarnoubHuman Oncology and Pathogenesis Program, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.ORCID 0000-0003-0823-1519
Jessica YangDepartment of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Imane El-DikaDepartment of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Devika RaoDepartment of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Joshi SmitaDepartment of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Michael FooteMemorial Sloan Kettering Cancer Center.ORCID 0000-0003-3027-2405
Ryan SugarmanDepartment of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
James HardingDepartment of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Andrew EpsteinMemorial Sloan Kettering Cancer Center.
David KelsenMemorial Sloan Kettering Cancer Center.
Sree ChalasaniDepartment of Medicine, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Fergus KeaneDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research.
Joshua SchoenfeldDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Anupriya SinghalMemorial Sloan Kettering Cancer Center.
Erin DiguglielmoDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research.
Chaitanya BandlamudiMemorial Sloan Kettering Cancer Center.ORCID 0000-0003-1108-4919
Junmin SongDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.
Hulya Sahin OzkanHuman Oncology and Pathogenesis Program, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.ORCID 0000-0001-6718-405X
Jungeui HongMemorial Sloan Kettering Cancer Center.
Haochen ZhangValar Labs.ORCID 0000-0002-8292-9491
Agustin CardenasHuman Oncology and Pathogenesis Program, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.
Maria LaoHuman Oncology and Pathogenesis Program, David M. Rubenstein Center for Pancreas Cancer Research, Memorial Sloan Kettering Cancer Center.
Jerry MelchorMemorial Sloan Kettering Cancer Center.
Ronak ShahDepartment of Pathology and Laboratory Medicine, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center.
Wenfei KangMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center.
Francesca MazzoniMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center.
Kevin SoaresDepartment of Surgery, Immuno-Oncology Program, The Olayan Center for Cancer Vaccines, Memorial Sloan Kettering Cancer Center.
Mark DonoghueMemorial Sloan Kettering Cancer Center.ORCID 0000-0003-4538-6069
Vinod BalachandranMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-2956-223X
Mark SchattnerMemorial Sloan Kettering Cancer Center.
Ernesto SantosDepartment of Radiology, Memorial Sloan Kettering Cancer Center.ORCID 0000-0001-7185-1935
Vineet RolstonDepartment of Medicine, David M. Rubenstein Center for Pancreas Cancer Research, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Marsha ReyngoldDepartment of Radiology, David M. Rubenstein Center for Pancreas Cancer Research, Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center.
Alice WeiMemorial Sloan Kettering.ORCID 0000-0002-2505-959X
Ramzi HomsiDepartment of Pathology and Laboratory Medicine, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center.
Murray TippingMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center.
Olca BasturkMemorial Sloan Kettering Cancer Center.ORCID 0000-0003-2747-1366
Michael BergerMemorial Sloan Kettering Cancer Center.ORCID 0000-0003-3882-5000
Richard DoMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-6554-0310
William JarnaginMemorial Sloan-Kettering Cancer Center.
Nadeem RiazMemorial Sloan Kettering Cancer Center.ORCID 0000-0001-9873-5862
Dana Pe'erMemorial Sloan Kettering Cancer Center.ORCID 0000-0002-9259-8817
Marinela CapanuMemorial Sloan Kettering Cancer Center.
Christine Iacobuzio-DonahueORCID 0000-0002-4672-3023
Eileen O'ReillyORCID 0000-0002-8076-9199
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTotal Neoadjuvant Therapy (TNT) for Borderline Resectable and Locally Advanced Pancreatic AdenocarcinomaP50CA257881 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Alice Chia- chi Wei · 2022 to 2026
$14.3MMSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3MImproving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)U01CA238444 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CERCEK, ANDREA, IACOBUZIO-DONAHUE, CHRISTINE A · 2020 to 2024
$3.3MHomologous recombination repair pathway mutations and genetic mechanisms shaping anti-tumor immunity and immunotherapy efficacyR01CA294640 · NCI · CLEVELAND CLINIC LERNER COM-CWRU · PI Timothy An-thy Chan, Nadeem Riaz · 2025 to 2026
$1.4MDefining the role of GNAS in gastrointestinal metastasisK08CA279922 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Foote · 2023 to 2026
$1.1MNCI NIH HHS K08 CA279922NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA257881NCI NIH HHS R01 CA294640NCI NIH HHS U01 CA238444
Abstract
The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib in 63 participants with metastatic pancreatic cancer with disease control on platinum-based chemotherapy. Participants were prospectively stratified into three cohorts by type of HRD: Cohort A (homologous recombination deficient [HRD] by
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.